Patents by Inventor Ellen Puré

Ellen Puré has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DISRUPTING TUMOR TISSUES BY TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP)
    Publication number: 20250011472
    Abstract: The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (FAP) for use in treating diseases, disorders or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.
    Type: Application
    Filed: July 18, 2024
    Publication date: January 9, 2025
    Inventors: Steven A. Albelda, Ellen Puré, Leslie Todd
  • Monoclonal Antibody Against Canine Fibroblast Activation Protein that Cross-Reacts with Mouse and Human Fibroblast Activation Protein (FAP)
    Publication number: 20240384004
    Abstract: The present invention relates to antibodies, binding polypeptides, and scFvs specific for fibroblast activation protein (FAP) capable of cross reacting with canine, mouse, and human FAP.
    Type: Application
    Filed: February 28, 2024
    Publication date: November 21, 2024
    Inventors: Ellen Puré, Leslie Todd
  • Monoclonal antibody against canine fibroblast activation protein that cross-reacts with mouse and human fibroblast activation protein (FAP)
    Patent number: 12139550
    Abstract: The present invention relates to antibodies, binding polypeptides, and scFvs specific for fibroblast activation protein (FAP) capable of cross reacting with canine, mouse, and human FAP.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: November 12, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ellen Puré, Leslie Todd
  • Disrupting tumor tissues by targeting fibroblast activation protein (FAP)
    Patent number: 12116418
    Abstract: The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (FAP) for use in treating diseases, disorders or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: October 15, 2024
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Steven A. Albelda, Ellen Puré, Leslie Todd
  • Compositions and Methods for Treating Heart Disease via Redirected T Cell Immunotherapies
    Publication number: 20240016848
    Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.
    Type: Application
    Filed: September 6, 2023
    Publication date: January 18, 2024
    Inventors: Jonathan Epstein, Haig Aghajanian, Steven M. Albelda, Ellen Puré
  • Compositions and Methods for Targeting Stromal Cells for the Treatment of Cancer
    Publication number: 20230416408
    Abstract: The present invention provides compositions and methods for treating cancer in a human. The invention relates to targeting the stromal cell population in a tumor microenvironment. For example, in one embodiment, the invention provides a composition that is targeted to fibroblast activation protein (FAP). The invention includes a chimeric antigen receptor (CAR) which comprises an anti-FAP domain, a transmembrane domain, and a CD3zeta signaling domain.
    Type: Application
    Filed: June 16, 2023
    Publication date: December 28, 2023
    Inventors: Carl H. June, Ellen Puré, Liang-Chuan Wang, Steven Albelda, John Scholler
  • Methods for treating heart disease via redirected T cell immunotherapies
    Patent number: 11786551
    Abstract: The present invention includes compositions and methods for treating heart disease and/or heart failure. In one embodiment, the treatment includes administering to the subject a cell genetically modified to express a chimeric antigen receptor (CAR), comprising an antigen binding domain specific for fibroblast activation protein (FAP). In another embodiment, the treatment includes administering a cell genetically modified to express a T cell receptor (TCR) specific for an activated fibroblast.
    Type: Grant
    Filed: September 25, 2018
    Date of Patent: October 17, 2023
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Jonathan Epstein, Haig Aghajanian, Steven M. Albelda, Ellen Puré
  • Monoclonal Antibody Against Canine Fibroblast Activation Protein that Cross-Reacts with Mouse and Human Fibroblast Activation Protein (FAP)
    Publication number: 20210087294
    Abstract: The present invention relates to antibodies, binding polypeptides, and scFvs specific for fibroblast activation protein (FAP) capable of cross reacting with canine, mouse, and human FAP.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: Ellen Puré, Leslie Todd
  • DISRUPTING TUMOR TISSUES BY TARGETING FIBROBLAST ACTIVATION PROTEIN (FAP)
    Publication number: 20210087295
    Abstract: The present invention relates to compositions and methods comprising a chimeric antigen receptor (CAR) capable of binding fibroblast activation protein (FAP) for use in treating diseases, disorders or conditions associated with the expression of FAP on canine, mouse, or human tumor-associated cells.
    Type: Application
    Filed: September 23, 2020
    Publication date: March 25, 2021
    Inventors: Steven A. Albelda, Ellen Puré, Leslie Todd